Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000
Debt
Debt-to-Equity Ratio2.48
Current Ratio6.51
Quick Ratio6.51
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$130.96 million
Price / Sales25.78
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book175.65
Profitability
EPS (Most Recent Fiscal Year)($14.38)
Net Income$-360,360,000.00
Net Margins-215.30%
Return on Equity-614.15%
Return on Assets-66.82%
Miscellaneous
Employees507
Outstanding Shares29,570,000
Market Cap$3.38 billion
Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions
What is Intercept Pharmaceuticals' stock symbol?
Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
How were Intercept Pharmaceuticals' earnings last quarter?
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($2.58) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.83) by $0.25. The biopharmaceutical company had revenue of $43.58 million for the quarter, compared to analyst estimates of $41.26 million. Intercept Pharmaceuticals had a negative net margin of 215.30% and a negative return on equity of 614.15%. The company's revenue was up 41.1% on a year-over-year basis. During the same quarter last year, the firm earned ($3.46) EPS. View Intercept Pharmaceuticals' Earnings History.
When is Intercept Pharmaceuticals' next earnings date?
What price target have analysts set for ICPT?
21 brokers have issued 1 year price objectives for Intercept Pharmaceuticals' stock. Their predictions range from $57.00 to $253.00. On average, they anticipate Intercept Pharmaceuticals' stock price to reach $131.85 in the next year. This suggests a possible upside of 15.5% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.
What is the consensus analysts' recommendation for Intercept Pharmaceuticals?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 1 sell rating, 9 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.
What are Wall Street analysts saying about Intercept Pharmaceuticals stock?
Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Intercept’s second-quarter results were encouraging as Ocailva sales started to recover with the drug achieving the highest level of prescriptions since launch. The company posted a narrower-than-expected loss in the second quarter while sales beat estimates. The company reiterated its previously provided guidance. Sales had earlier taken a hit due to the safety issues regarding Ocaliva. Nevertheless, management’s efforts to increase awareness about the updated level and promote Ocaliva, thereafter, is reaping results. Moreover, the company is looking to expand the drug’s label in the promising NASH space. The label expansion of the drug will boost the growth prospects. Moreover, the NASH market represents huge potential and a tentative approval will boost Ocaliva’s prospects. Shares have outperformed the industry in the year so far." (8/7/2018)
- 2. Needham & Company LLC analysts commented, "Intercept reported $34.5M in U.S. Ocaliva sales (+21% q/q; +24% y/y), slightly above our $34.0M and consensus $32M ests. WW sales were $43.2M, above our $43.0M and consensus $41M ests. Sales growth driven primarily by increased volume w/ early adopter prescriber base. Company expects some weakness in 3Q18 (summer), but reiterated 2018 WW sales guidance of $170-$185M. Phase 3 NASH timelines are unch, w/ REGENERATE trial results still expected 1H19. We are biased towards a positive outcome. Maintain HOLD given key milestone is in 2019." (8/2/2018)
- 3. Cantor Fitzgerald analysts commented, "PBC – Despite headwinds associated with labeling harmonization for Ocaliva and widened gross-to-net impact expected for the earlier portion of the year, scripts for the drug have been reported to have stabilized. We believe efforts towards educating and creating confidence for prescribing physicians may have stemmed the tide and signal the return to revenue growth. While our long-term projections remain conservative (20% at peak), continued execution in the remainder of 2018 could build our confidence and expand opportunity for the shares. That said, we remain cautious on NASH." (5/8/2018)
Who are some of Intercept Pharmaceuticals' key competitors?
Some companies that are related to Intercept Pharmaceuticals include Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Genmab A/S (GNMSF), Nektar Therapeutics (NKTR), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Bausch Health Companies (BHC), Valeant Pharmaceuticals (VRX), Amneal Pharmaceuticals (AMRX), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS) and Alkermes (ALKS).
Who are Intercept Pharmaceuticals' key executives?
Intercept Pharmaceuticals' management team includes the folowing people:
- Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 50)
- Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 48)
- Mr. Jerome B. Durso, Chief Operating Officer (Age 50)
- Mr. David Ford, Chief HR Officer (Age 49)
- Dr. David Shapiro, Chief Medical Officer (Age 64)
Who are Intercept Pharmaceuticals' major shareholders?
Intercept Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), FMR LLC (15.01%), Senvest Management LLC (3.30%), First Trust Advisors LP (2.84%), Northern Trust Corp (0.87%) and Pinnacle Associates Ltd. (0.60%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.
Which institutional investors are selling Intercept Pharmaceuticals stock?
ICPT stock was sold by a variety of institutional investors in the last quarter, including Senvest Management LLC, Millennium Management LLC, Spark Investment Management LLC, SG Americas Securities LLC, Pinnacle Associates Ltd., State Board of Administration of Florida Retirement System, Bellevue Group AG and Bank of Montreal Can. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include David Shapiro, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Insider Buying and Selling for Intercept Pharmaceuticals.
Which institutional investors are buying Intercept Pharmaceuticals stock?
ICPT stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, Northern Trust Corp, Schwab Charles Investment Management Inc., Alps Advisors Inc., Peregrine Capital Management LLC, ING Groep NV and Asymmetry Capital Management L.P.. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener and Mark Pruzanski. View Insider Buying and Selling for Intercept Pharmaceuticals.
How do I buy shares of Intercept Pharmaceuticals?
Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intercept Pharmaceuticals' stock price today?
One share of ICPT stock can currently be purchased for approximately $114.17.
How big of a company is Intercept Pharmaceuticals?
Intercept Pharmaceuticals has a market capitalization of $3.38 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,360,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Intercept Pharmaceuticals employs 507 workers across the globe.
What is Intercept Pharmaceuticals' official website?
How can I contact Intercept Pharmaceuticals?
Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]
MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
